Bringing the fundamentals into focus…
Back to CRISPR Therapeutics AG
How CRISPR Therapeutics AG stacks up
CRSP · against 237 other Healthcare companies of similar size
Profitability
5/ 100
Near the bottom of its peers.
Ranked #230 of 238 · scores higher than 3% of peers
Bars: peers in each 10-point band of the profitability score13 peers with a profitability score of 0–9, including CRSP · Click a bar to see the companies
Why profitability scores 5?
Weighted metrics compared with all Healthcare companies.Mainly because of its operating margin, return on assets and return on invested capital, which are weaker than most Healthcare peers.
- a thinner operating margin: weaker than 97% of peers. Operating margin: -3990.0% vs peer median 7.1%
- a lower return on assets: weaker than 79% of peers. Return on assets: -17.0% vs peer median 1.7%
- a lower return on invested capital: weaker than 79% of peers. Return on invested capital: -20.7% vs peer median 4.7%
Metric by metric
Position: dot = CRSP, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | CRSP | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 231 reported | -20.7% | 8.2% | 17% | 33% | |
| Operating marginHigher is better · 217 reported | -3990.0% | 11.0% | 3% | 33% | |
| Return on assetsHigher is better · 227 reported | -17.0% | 2.9% | 16% | 33% | |
| Return on equityHigher is better · 222 reported | -26.1% | 7.5% | 21% | Context only | |
| Gross marginHigher is better · 245 reported | 0.0% | 49.5% | 2% | Context only |
Ranking by profitability score
Top 5 and the companies ranked around CRSP| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 321.5B INR (≈$3.9B) | 100 | 70 | |
| 3 | 51.3B ZAR (≈$2.8B) | 99 | 73 | |
| 3 | 3.8B USD | 99 | 71 | |
| 3 | 2.7B USD | 99 | 84 | |
| 226 | 3.3B USD | 9 | 39 | |
| 228 | 5.4B USD | 8 | 24 | |
| 229 | 2.8B USD | 7 | 51 | |
| 230 | 5.7B USD | 5 | 52 | |
| 230 | 4.8B USD | 5 | 27 | |
| 230 | 4.6B USD | 5 | 29 | |
| 233 | 3.8B USD | 4 | 48 | |
| 233 | 3.7B USD | 4 | 28 | |
| 235 | 3.1B USD | 3 | 27 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score